IntelGenx Technologies Corp. (OTCMKTS:IGXT) Files An 8-K Other Events
Item 8.01 Other Events
| – | News Release |
Oral Film Exclusivity Granted to IntelGenx VersaFilmTM
for Tadalafil Erectile Dysfunction Dosing Patent
| Exhibit | Description |
| 99.1 | Press Release |
About IntelGenx Technologies Corp. (OTCMKTS:IGXT)
IntelGenx Technologies Corp. is a drug delivery company focused on the development of oral immediate-release and controlled-release products. The Company also focuses on developing pharmaceutical products based on its drug delivery technologies. Its product development efforts are based upon over three delivery platform technologies, such as VersaFilm, an oral film technology; VersaTab, a multilayer tablet technology, and AdVersa, a mucoadhesive tablet technology. The VersaFilm technology consists of a thin (25 to 35 micron) polymeric film consisting of the United States Pharmacopeia (USP) components for use in food, pharmaceutical and cosmetic products. Its Multilayer Tablet platform technology allows for the development of oral controlled-release products. Its product portfolio includes INT0001/2004, INT0004/2006, INT0007/2006, INT0008/2007, INT0010/2006, INT0027/2011, INT0030/2011, INT0036/2013, INT0037/2013, INT0039/2013, INT0040/2014, INT0041/2015, INT0042/2015 and INT0043/2015. IntelGenx Technologies Corp. (OTCMKTS:IGXT) Recent Trading Information
IntelGenx Technologies Corp. (OTCMKTS:IGXT) closed its last trading session 00.000 at 0.680 with 141,332 shares trading hands.
